133 related articles for article (PubMed ID: 12920423)
41. Pharmacotherapy of obsessive-compulsive disorder.
Klein DF
Encephale; 1990; 16 Spec No():331-4. PubMed ID: 2209491
[TBL] [Abstract][Full Text] [Related]
42. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
43. [Unexpected loss of therapeutic effect of oxcarbazepine].
Lampert ML; Rätz Bravo AE; Brugger S; Haschke M
Praxis (Bern 1994); 2007 Nov; 96(47):1843-8. PubMed ID: 18062156
[TBL] [Abstract][Full Text] [Related]
44. Oxcarbazepine and hepatic porphyria.
Pierach CA
Epilepsia; 2002 Apr; 43(4):455; discussion 455. PubMed ID: 11952779
[No Abstract] [Full Text] [Related]
45. Scheme-based benzodiazepine detoxification with oxcarbazepine -- a case report.
Croissant B; Grosshans M; Klein O; Diehl A; Mann K
Pharmacopsychiatry; 2005 Sep; 38(5):222-3. PubMed ID: 16189750
[TBL] [Abstract][Full Text] [Related]
46. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of clomipramine for obsessive-compulsive symptoms and chronic pain in two patients with schizophrenia.
Kurokawa K; Tanino R
J Clin Psychopharmacol; 1997 Aug; 17(4):329-30. PubMed ID: 9241021
[No Abstract] [Full Text] [Related]
48. Central hypothyroidism with oxcarbazepine therapy.
Miller J; Carney P
Pediatr Neurol; 2006 Mar; 34(3):242-4. PubMed ID: 16504798
[TBL] [Abstract][Full Text] [Related]
49. Oxcarbazepine for the treatment of binge eating disorder: a case series.
Leombruni P; Gastaldi F; Lavagnino L; Fassino S
Adv Ther; 2008 Jul; 25(7):718-24. PubMed ID: 18636233
[TBL] [Abstract][Full Text] [Related]
50. Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds.
Potter WZ; Ketter TA
Can J Psychiatry; 1993 Apr; 38(3 Suppl 2):S51-6. PubMed ID: 8500079
[TBL] [Abstract][Full Text] [Related]
51. A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals.
Andersen SL; Greene-Colozzi EA; Sonntag KC
Biol Psychiatry; 2010 Oct; 68(8):741-7. PubMed ID: 20619828
[TBL] [Abstract][Full Text] [Related]
52. Oxcarbazepine: a review.
Shorvon S
Seizure; 2000 Mar; 9(2):75-9. PubMed ID: 10845729
[No Abstract] [Full Text] [Related]
53. Oxcarbazepine induced hyponatremic coma.
Paliwal V; Garg RK; Kar AM; Singh MK
Neurol India; 2006 Jun; 54(2):214-5. PubMed ID: 16804276
[No Abstract] [Full Text] [Related]
54. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.
Uzun O
J Psychopharmacol; 2010 Mar; 24(3):425-7. PubMed ID: 19010977
[TBL] [Abstract][Full Text] [Related]
55. Oxcarbazepine in glossopharyngeal neuralgia: clinical response and effect on serum lipids.
Luef G; Poewe W
Neurology; 2004 Dec; 63(12):2447-8. PubMed ID: 15623731
[No Abstract] [Full Text] [Related]
56. Oxcarbazepine-related retrograde ejaculation.
Calabrò RS; Italiano D; Pollicino P; Bramanti P
Epilepsy Behav; 2012 Oct; 25(2):174-5. PubMed ID: 23032126
[No Abstract] [Full Text] [Related]
57. Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder.
Suppes T; Kelly DI; Hynan LS; Snow DE; Sureddi S; Foster B; Curley E
Aust N Z J Psychiatry; 2007 May; 41(5):397-402. PubMed ID: 17464731
[TBL] [Abstract][Full Text] [Related]
58. Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination.
Conforti D; Borgherini G; Fiorellini Bernardis LA; Magni G
Int Clin Psychopharmacol; 1999 May; 14(3):197-8. PubMed ID: 10435776
[TBL] [Abstract][Full Text] [Related]
59. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report.
Pasquini M; Garavini A; Biondi M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):157-9. PubMed ID: 15610960
[TBL] [Abstract][Full Text] [Related]
60. Fluvoxamine treatment of body dysmorphic disorder.
Hollander E; Cohen L; Simeon D; Rosen J; DeCaria C; Stein DJ
J Clin Psychopharmacol; 1994 Feb; 14(1):75-7. PubMed ID: 8151008
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
